CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor
Status:
Recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
This study is being conducted to test the safety and efficacy of ramucirumab in combination
with other chemotherapy in the treatment of relapsed, recurrent, or refractory desmoplastic
small round cell tumor (DSRCT) in children and young adults. This trial is part of the
CAMPFIRE master protocol which is a platform to accelerate the development of new treatments
for pediatric and young adult participants with cancer. Your participation in this trial
could last 12 months or longer, depending on how you and your tumor respond.